Patents by Inventor Craig J. Eagle

Craig J. Eagle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination of local rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer
    Patent number: 10471144
    Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: November 12, 2019
    Assignees: Provectus Pharmatech, Inc., Pfizer, Inc.
    Inventors: Craig J. Eagle, H. Craig Dees, Eric A. Wachter, Jamie Singer
  • Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer
    Publication number: 20180055926
    Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
    Type: Application
    Filed: November 6, 2017
    Publication date: March 1, 2018
    Applicants: Provectus Pharmatech, Inc., Pfizer, Inc.
    Inventors: Craig J. EAGLE, H. Craig DEES, Eric A. WACHTER, Jamie SINGER
  • Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer
    Patent number: 9839688
    Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: December 12, 2017
    Assignees: Provectus Pharmatech, Inc., Pfizer, Inc.
    Inventors: Craig J. Eagle, H. Craig Dees, Eric A. Wachter, Jamie Singer
  • Combination of local and systemic immunomodulative therapies for melanoma and liver cancer
    Patent number: 9808524
    Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: November 7, 2017
    Assignees: Provectus Pharmatech, Inc., Pfizer, Inc.
    Inventors: Craig J. Eagle, H. Craig Dees, Eric A. Wachter, Jamie Singer
  • Combination of local and systemic immunomodulative therapies for melanoma and liver cancer
    Patent number: 9750807
    Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: September 5, 2017
    Assignees: Provectus Pharmatech, Inc., Pfizer, Inc.
    Inventors: Craig J. Eagle, H. Craig Dees, Eric A. Wachter, Jamie Singer
  • Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer
    Publication number: 20150290318
    Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
    Type: Application
    Filed: June 24, 2015
    Publication date: October 15, 2015
    Applicants: Provectus Pharmaceuticals, Inc., Pfizer, Inc.
    Inventors: Craig J. Eagle, H. Craig Dees, Eric A. Wachter, Jamie Singer
  • Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer
    Publication number: 20150290165
    Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
    Type: Application
    Filed: June 24, 2015
    Publication date: October 15, 2015
    Applicants: Provectus Pharmaceuticals, Inc., Pfizer, Inc.
    Inventors: Craig J. EAGLE, H. Craig DEES, Eric A. WACHTER, Jamie SINGER
  • Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
    Patent number: 9107887
    Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: August 18, 2015
    Assignees: Provectus Pharmaceuticals, Inc., Pfizer, Inc.
    Inventors: Craig J. Eagle, H. Craig Dees, Eric A. Wachter, Jamie Singer
  • Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer
    Publication number: 20120263677
    Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
    Type: Application
    Filed: March 9, 2012
    Publication date: October 18, 2012
    Inventors: Craig J. Eagle, H. Craig Dees, Eric A. Wachter, Jamie Singer